HIF1A and cervical carcinoma: Twenty confirmed HIF-1 inhibitors including cardiac glycosides; topoisomerase inhibitors; RAS–RAF–MEK–ERK pathway inhibitors; and AKT–PI3K–mTOR pathway inhibitors, were tested for their anti-proliferative activity over three days in human colon cancer HCT116 cells and human cervical cancer ME-180 cells (Table S8).